A ascensão de Genai traz uma tremenda oportunidade. Mas, para reduzir o hype e identificar futuros vencedores, os investidores devem se concentrar em quatro pontos quentes da inovação.
EDUCAÇÃO
- MD, Instituto Karolinska, Estocolmo
- PhD em Epidemiologia Clínica, Karolinska Institute, Estocolm || 3453. solutions
Honors and Awards
- Board member of startup company OnDosis focusing on novel drug device solutions
- Board member of Swedish Medical Association
Adina Symreng joined Boston Consulting Group in September 2020. She is a core member of both the Health Care and Principal Investors & Private Equity (PIPE) practices at the firm.
She is an expert in health care strategy, large-scale transformations, and health tech, and leads BCG’s work with payers and fornecedores nos nórdicos. Adina ingressou na BCG em 2013. Ela saiu para servir a empresa global da Medtech Elekta em 2018, mais recentemente como chefe global de estratégia corporativa, antes de retornar ao BCG em 2020.
As a member of the Health Care practice, Adina has worked in all aspects of health care including biopharma, medtech, health care payers and providers, life science tools, in vitro diagnostics (IVD), and investors, across Europe, the US, and the Middle East. She has had more than ten papers published in peer reviewed scientific journals.
